(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 November 2014 (27.11.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/190157 A8

(51) International Patent Classification:
C12N 15/113 (2010.01) *C12N 9/64* (2006.01)
A61K 31/713 (2006.01)

(21) International Application Number:
PCT/US2014/039149

(22) International Filing Date:
22 May 2014 (22.05.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/826,178 22 May 2013 (22.05.2013) US
61/912,988 6 December 2013 (06.12.2013) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.** [US/US]; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US).

(72) Inventors: **BUTLER, James**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **BETTENCOURT, Brian**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **RAJEEV, Kallanthottathil, G.**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **MAIER, Martin**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **CHARISSE, Klaus**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US).

(74) Agents: **ZACHARAKIS, Maria Laccotripe** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,

[Continued on next page]

(54) Title: TMPRSS6 IRNA COMPOSITIONS AND METHODS OF USE THEREOF




Figure 1

(57) Abstract: The invention relates to RNAi agents, e.g., double- stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as β-thalassemia or hemochromatosis.

WO 2014/190157 A8

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) **Date of publication of this corrected version**:
19 November 2015

(15) **Information about Correction**:
see Notice of 19 November 2015